Related references
Note: Only part of the references are listed.Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme
Filiz Senbabaoglu et al.
CANCER BIOLOGY & THERAPY (2016)
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis
Jaclyn Andricovich et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
The BCL-2 protein family, BH3-mimetics and cancer therapy
A. R. D. Delbridge et al.
CELL DEATH AND DIFFERENTIATION (2015)
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
J. D. Leverson et al.
CELL DEATH & DISEASE (2015)
NDY1/KDM2B Functions as a Master Regulator of Polycomb Complexes and Controls Self-Renewal of Breast Cancer Stem Cells
Filippos Kottakis et al.
CANCER RESEARCH (2014)
Getting TRAIL back on track for cancer therapy
J. Lemke et al.
CELL DEATH AND DIFFERENTIATION (2014)
Epigenetic inactivation of DAPK1, p14ARF, mir-34a and-34b/c in acute promyelocytic leukaemia
Ho Yin Ng et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Association between DAPK1 Promoter Methylation and Cervical Cancer: A Meta-Analysis
Jiaqiang Xiong et al.
PLOS ONE (2014)
Exploiting epigenetic vulnerabilities for cancer therapeutics
Barbara Mair et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Rongqing Pan et al.
CANCER DISCOVERY (2014)
ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection
Hannah K. Long et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Francois Vaillant et al.
CANCER CELL (2013)
Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors
T. Bagci-Onder et al.
ONCOGENE (2013)
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
L. Y. Dimberg et al.
ONCOGENE (2013)
Epigenetic Reprogramming in Cancer
Mario L. Suva et al.
SCIENCE (2013)
Chromatin remodeling in Cancer: A Gateway to regulate gene Transcription
Sujit S. Nair et al.
MOLECULAR ONCOLOGY (2012)
Chromatin-modifying enzymes as modulators of reprogramming
Tamer T. Onder et al.
NATURE (2012)
Kdm2b promotes induced pluripotent stem cell generation by facilitating gene activation early in reprogramming
Gaoyang Liang et al.
NATURE CELL BIOLOGY (2012)
Evaluating the Effect of Therapeutic Stem Cells on TRAIL Resistant and Sensitive Medulloblastomas
Irina Nesterenko et al.
PLOS ONE (2012)
KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia
Jin He et al.
BLOOD (2011)
A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell-Delivered TRAIL in Experimental Glioma Models
Tugba Bagci-Onder et al.
CANCER RESEARCH (2011)
F-box protein 10, an NF-κB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway
R. Ge et al.
CELL DEATH AND DIFFERENTIATION (2011)
Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis
Thomas Unterkircher et al.
CLINICAL CANCER RESEARCH (2011)
Cancer epigenetics reaches mainstream oncology
Manuel Rodriguez-Paredes et al.
NATURE MEDICINE (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma
Bernhard Gillissen et al.
JOURNAL OF CELL BIOLOGY (2010)
Differential expression analysis for sequence count data
Simon Anders et al.
GENOME BIOLOGY (2010)
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
Meike Vogler et al.
BLOOD (2009)
Epigenetic Silencing of Death Receptor 4 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Gliomas
Agnes Elias et al.
CLINICAL CANCER RESEARCH (2009)
Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL
Dolly G. Aguilera et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide
Shawn Hingtgen et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Members of a family of JmjC domain-containing oncoproteins immortalize embryonic fibroblasts via a JmjC domain-dependent process
Raymond Pfau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells
P. Grabarczyk et al.
ONCOGENE (2007)
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
S. Fulda et al.
ONCOGENE (2006)
SAHA-sensitized prostate cancer cells to TNFα-related apoptosis-inducing ligand (TRAIL):: Mechanisms leading to synergistic apoptosis
Vijavabaskar Lakshmikanthan et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Critical role for DP5/Harakiri, a Bcl-2 homology domain 3-only Bcl-2 family member, in axotomy-induced neuronal cell death
K Imaizumi et al.
JOURNAL OF NEUROSCIENCE (2004)
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
R Edgar et al.
NUCLEIC ACIDS RESEARCH (2002)
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
K Takeda et al.
NATURE MEDICINE (2001)
Share Paper
